



Antimicrobial Constituents Of Conyza Floribunda

Corresponding Author:

Prof. Lawrence Manguro,
Associate Professor, Chemistry, 40105 - Kenya

Submitting Author:

Prof. Lawrence O Manguro,
Associate Professor, Chemistry, 40105 - Kenya

Article ID: WMC00842

Article Type: Research articles

Submitted on:30-Sep-2010, 01:35:49 PM GMT **Published on:** 30-Sep-2010, 04:55:41 PM GMT

Article URL: http://www.webmedcentral.com/article_view/842

Subject Categories:PHARMACOLOGY

Keywords:Conyza floribunda, Asteraceae, Active principles, Antimicrobial Activity

How to cite the article:Manguro L , Ogur J , Opiyo S . Antimicrobial Constituents Of Conyza Floribunda .
WebmedCentral PHARMACOLOGY 2010;1(9):WMC00842

Source(s) of Funding:

None

Competing Interests:

We have no competing interest

Additional Files:

[structures](#)

[structures](#)

Antimicrobial Constituents Of *Conyza Floribunda*

Author(s): Manguro L , Ogur J , Opiyo S

Abstract

The study describes the antibacterial and antifungal effects of both CH₂Cl₂ and MeOH crude extracts, collected fractions and pure isolates of *Conyza floribunda*. The antimicrobial activity tests were carried out using agar diffusion method. *In vitro* tests using CH₂Cl₂ and MeOH extracts of *C. floribunda* showed anti-bacterial activities against *Streptococcus pneumoniae*, *Staphylococcus aureus* and *Escherichia coli*, and antifungal activities against *Candida albicans*, *Trichophyton mentagrophytes* and *Microsporum gypseum*. The antibacterial and antifungal principles from *C. floribunda* were found to be (24S)-ethylcholesta-5, 22E, 25-dien-3-O-b-glucoside and cyasterone from methanol extract, and 3-oxofriedooleanane and betullinic acid associated with CH₂Cl₂ extract. The results of the present study indicate that the plant could be a useful remedy for some of the disease conditions caused by the tested bacteria and fungi and the isolated compounds could be good

Introduction

The genus *Conyza* (Asteraceae) comprises of about fifty species, which are mainly found in tropical and subtropical regions [1, 2]. In Kenya, the genus is represented by twenty four species, distributed country wide and one such species is *Conyza floribunda*. The plant grows up to 3 m tall when fully mature and is common in wet regions along the road sides, gardens and in disturbed soils within altitudes of 400-2000m above sea level [3]. It is traditionally used for a variety of pharmacological applications including treatment of smallpox, chickenpox, soar throat, ringworm and other skin related diseases, toothache and to stop bleeding from injuries [4]. Previous phytochemical studies on the plant are scarce. However, studies on other related species have lead to the isolation of secondary metabolites, some of which have been reported to exhibit biological activities including antiinflammatory [5-7], antitumor [8, 9] and antioxidants [10, 11]. In the present study, we report the bioassay guided fractionation of CH₂Cl₂ and MeOH extracts of the whole plant using agar well diffusion method.

Material and Methods

Instrumental analysis

The UV spectra were run on PYE UNICAM SP8-150 UV/Vis spectrophotometer. IR data were obtained on Perkins-Elmer 600 FTIR series using acetonitrile and KBr pellet. The NMR data were measured in CDCl₃ and CDCl₃-DMSO-d₆ on a Bruker NMR Ultrashed TM operating at 500 and 125 MHz, respectively. The MS data were obtained on a MAT 8200 A Varian Bremen instrument.

Plant material

Authenticated *Conyza floribunda* whole plant was collected at Maseno University Botanic garden in June 2005 and a voucher specimen deposited at the National Museum of Kenya (Voucher deposit number: 2005/06/01/SAO/CHEMMK). The whole plant was air-dried in the open and reduced to a powder using a Wiley mill.

Preparation of plant extracts

Dry powdered plant material (2 kg) was sequentially extracted with CH₂Cl₂ (3 L) and MeOH (3 L) by percolation for one week each time, with occasional shaking, thereafter filtered and then concentrated in vacuo to afford 65 g and 105 g of extracts, respectively.

Isolation and identification of compounds from CH₂Cl₂ extract

Approximately 60 g of the extract was dissolved in small amount of CH₂Cl₂ and adsorbed onto silica gel for column chromatography. Fractionation of the extract using gradient of n-hexane-ethyl acetate and MeOH afforded 300 fractions (20ml each) whose composition were monitored by TLC using solvent systems n-hexane-EtOAc (9:1; 4:1; 2:1) and CH₂Cl₂-MeOH (9:1 and 4:1), respectively. Fractions showing similar TLC profiles were combined resulting into four pools (I-IV).

Pool I (fractions 1-90, 7 g) contained mainly fatty acid and waxes and was discarded. Fractions 91-170 constituted pool II (15 g) and was found to contain two major spots which were further purified using medium pressure chromatography (pressure ≈ 1 bar), eluting with n-hexane-ethyl acetate (9:1 and 4:1) to give stigmasta-5, 22-dien-3-acetate (4, 175 mg) and 3-acetoxofriedooleanane (9, 95 mg) [12]. Pool III (fractions 171-250, 10 g) upon repeated fractionation using n-hexane-ethyl acetate (4:1 and 3:1) yielded

spinasta-7, 22-dien-3-ol (6, 75 mg), 3-oxofriedooleanane (7, 55 mg) and 3-hydroxfriedooleanane (8, 165 mg) [13]. Pool IV (6.5 g) gave stigmasta-5, 22-dien-3-ol (5, 100 mg) and betulinic acid (10, 85 mg) [12].

Isolation and identification of MeOH extract constituents

The extract (75 g) was pre-adsorbed onto silica gel and chromatographed with CH₂Cl₂-MeOH gradient to pure MeOH affording 120 fractions of 50 ml each. The composition of the fractions were monitored by TLC using CH₂Cl₂-MeOH (4:1, 3:2 and 1:1) and those that exhibited similar TLC profiles were combined to constitute two major pools (V and VI). Fractions 10-50 (pool V, 12 g) was further purified by chromatography using CH₂Cl₂-MeOH (9:1) followed by the same solvent system in the ratio 4:1 to give kaempferol (14, 85 mg), cyasterone (3, 78 mg), quercetin (12, 105 mg), myricetin (13, 55mg), 24-ethylcholesta-5, 22E, 25-triene 3-O-β-glucoside (2, 45 mg) and quercetin 3-O-β-glucoside (11, 105 mg) [12, 14]. The remaining fractions (pool VI, 3 g) contained two major compounds, which could not be obtained in pure form and were purified by preparative HPLC using acetonitrile-H₂O (35:65): mobile flow rate 10mLmin⁻¹; injecting 10μl each time to afford pure 24-ethylcholesta-5, 22E, 25-triene 3-O-β-glucoside (1'' → 4') rhamnoside (1) (tr=39 min, 93 mg) [13].

Antimicrobial assay

Test microorganisms

Three bacteria and three fungi, all locally isolated microorganisms (LIO) were obtained from New Nyanza General Hospital in Kisumu, Kenya. The bacterial pathogens were *Streptococcus pneumoniae*, *Staphylococcus aureus* (Gram positive) and *Escherichia coli* (Gram negative) while the fungal pathogens were *Candida albicans* (yeast fungus), *Trichophyton mentagrophytes* and *Microsporium gypseum* (filamentous fungi). The microorganisms were chosen on the basis of ethnobotanical information available on the plant.

Antibacterial screening

Antibacterial activity of crude extracts and pooled fractions was done using agar well diffusion method [17, 18]. The bacterial isolates were first grown on a nutrient broth (Oxoid) for 24 h before use. The inoculum suspensions were standardized to 107-108CFU/ml. Two hundred microliter of the standard cell suspensions was spread uniformly using a sterile glass spreader on a nutrient agar (Oxoid). Wells were then bored into the agar using a sterile 6 mm diameter cork borer. Approximately 100 μl of crude extracts (at 500 μg/ml) and pooled fractions at concentrations of 200 μg/ml were separately

introduced into the wells in the culture plates previously seeded with the test organisms, allowed to stand at room temperature for about one hour and then incubated at 37 °C for 24 h. Controls were set up in parallel using dimethylsulfoxide (DMSO) that was used to reconstitute the extracts. The plates were observed for zones of inhibition after 48 h. The effects of the extracts and pooled fractions were compared with those of chlorophenicol, ofloxacin and streptomycin at a concentration of 10μg/ml each.

Antifungal screening

The antifungal tests were done according to the known methods [19]. The fungal isolates were allowed to grow on a Sabouraud dextrose agar (SDA) (Oxoid) at 25°C until they sporulated. The fungal spores were standardized before use and one hundred microliter of the standardized fungal suspension was evenly spread on the SDA (oxoid) using a glass spreader. Wells were then bored into the agar media using a sterile 6mm cork borer and filled with solutions of crude extracts and pooled fractions at concentrations of 500 and 200 μg/ml, respectively. The plates were allowed to stand for 1 h for proper diffusion of the extracts and pooled fractions into the media. The plates were incubated at 25 °C for 72 h and later observed for zones of inhibition. Controls were set up in parallel using DMSO. The effect of the extracts on the fungal isolates was compared with fluconazole, cinamizole and amphotericin B at a concentration of 10 μg/ml each.

Minimum inhibitory concentration (MIC)

Minimum inhibitory concentration (MIC) of pure isolates was determined using standard procedures [20, 21], whereby the isolates were dissolved in DMSO and different concentrations ranging between 1000-1 μg/ml were prepared. The MIC was taken as the lowest concentration that prevented the growth of the test microorganism. The antifungal and antibacterial activities were done in four replicates (n=4).

Results

Phytochemical studies

Chromatographic fractionation of CH₂Cl₂ and MeOH extracts from *C. floribunda* whole plant afforded 24-ethylcholesta-5, 22E, 25-triene 3-O-β-glucoside (1'' → 4') rhamnoside (1), 24-ethylcholesta-5, 22E, 25-triene 3-O-β-glucoside (2), cyasterone (3), stigmasta-5, 22-dien-3-ol (5), spinasta-7, 22-dien-3-ol (6), 3-oxofriedooleanane (7), 3-hydroxfriedooleanane (8), 3-acetoxofriedooleanane (9), betulinic acid (10),

quercetin 3-O- β -glucoside (11), quercetin (12), myricetin (13), kaempferol (14) [12-14].

Antibacterial and antifungal activities of extracts, fractions and pure compounds

Dichloromethane and MeOH extracts showed activities against all the three bacteria tested in the study (Table 1). The MeOH extract strongly inhibited the growth of *S. pneumoniae* (16 ± 0.3) and *S. aureus* (16 ± 0.4) while *E. coli* (12 ± 0.5) was moderately inhibited. The MeOH extract was found to be more active in this respect than the CH_2Cl_2 . Similarly, in the antifungal tests, methanol extract exhibited stronger activities against *C. albicans* (19 ± 0.1) and *T. mentagrophytes* (16 ± 1.1) than the dichloromethane extract (Table 2). The MeOH extract also showed fairly moderate activity against *M. gypseum* (14 ± 0.3). It can also be noted that the bacteria and fungi tested were relatively more susceptible to MeOH extract than CH_2Cl_2 .

Fractionation of dichloromethane extract as previously discussed in the experimental section gave four pools (I-IV) which were bioassayed. With the exception of pool I, the remaining three pools displayed moderate and weak activities against bacteria tested (Table 3). Similarly, the methanolic extract upon chromatography with CH_2Cl_2 -MeOH gradient to pure MeOH constituted pools V and VI which exhibited similar antibacterial activities against all the bacteria tested (Table 3). In the antifungal tests (Table 4), pool II weakly inhibited the growth of *T. mentagrophytes* and *C. albicans* with values of 6 ± 10 and 4 ± 0.2 , respectively. No activity was observed with this pool for *M. gypseum*. Pools III and IV both from CH_2Cl_2 extract moderately inhibited the growth of *C. albicans* and *T. mentagrophytes* but failed to show any activity against *M. gypseum*. Similarly, fairly strong inhibitions were experienced with pools V and VI against *C. albicans* and *T. mentagrophytes*, however against *M. gypseum* the pools showed moderate activities. The two pools which were from MeOH extracts were better fungal growth inhibitors than those from CH_2Cl_2 extract.

In the determination of MIC (Table 5), out of the fourteen compounds isolated from *C. floribunda* only four showed activities against the tested pathogens. Although, pool II showed weak activities against *S. aureus*, *C. albicans* and *T. mentagrophytes*, these activities were not observed with the pure compounds 4 and 9 isolated from this pool. Compounds 2 from MeOH extract showed MIC value of $50\mu\text{g/ml}$ against both *S. pneumoniae* and *S. aureus* while for *E. coli* it gave a value $> 100\mu\text{g/ml}$. Similarly the compound exhibited MIC value of $25\mu\text{g/ml}$ for *C. albicans* but values of 50 and $100\mu\text{g/ml}$ were observed for *T. mentagrophytes* and *M. gypseum*, respectively. On the

other hand, compound 3 inhibited the growth of both *S. pneumoniae* and *S. aureus* by showing a MIC value $50\mu\text{g/ml}$ while the value for *E. coli* was $100\mu\text{g/ml}$. The same compound gave MIC value of $25\mu\text{g/ml}$ against *C. albicans* and $50\mu\text{g/ml}$ for both *T. mentagrophytes* and *M. gypseum*. The other compound that showed slight activity was 7 which gave MIC value of $100\mu\text{g/ml}$ against both *S. aureus* and *S. pneumoniae* and almost no activity against *E. coli* ($>200\mu\text{g/ml}$). Similarly, the same compound was observed to be active against *C. albicans* and *T. mentagrophytes* with MIC value of $100\mu\text{g/ml}$ but not active against *M. gypseum*. Compound 10 isolated from CH_2Cl_2 showed MIC value of $100\mu\text{g/ml}$ for both *S. pneumoniae* and *S. aureus* and greater than $200\mu\text{g/ml}$ for *E. coli*. In the antifungal tests, it was found to be active against *C. albicans* with MIC value of $50\mu\text{g/ml}$ and moderately active against *T. mentagrophytes* ($100\mu\text{g/ml}$) but inactive against *M. gypseum*.

Discussion and Conclusion.

The study showed that extracts from *C. floribunda* have antifungal and antibacterial activities and this is probably why the plant is widely used in traditional medicine. The extracts from the plant have broad spectrum activity since they are effective against both gram positive and gram negative bacteria. The extracts were also active against dermatophytic fungi, *T. mentagrophytes* and *M. gypseum*. This observation is of particular interest since many Kenyan traditional healers use the plant for treating ringworm, a type of infection caused by the two fungi above. The extracts were also found to be active against *C. albicans*, a ubiquitous fungi associated with the pathogenesis of urinary tract infections and oral thrush [15,16]. Methanol extract exhibited higher activity compared to dichloromethane and this could be attributed to the fact that antibacterial and antifungal compounds in *C. floribunda* are polar compounds which could be extracted with polar solvents such as methanol and water. The antibacterial and antifungal principles from *C. floribunda* were identified as (24S)-ethylcholesta-5,22E, 25-trienene 3-O-glucopyranoside (2), cyasterone (3), 3-oxofriedooleanane (7) and betulinic acid (10). Compounds 2 and 3 both from MeOH extract showed both antibacterial and antifungal activities and were more effective than the latter two. This observation suggests that the antifungal principles in the plant have broad spectrum antifungal activities.

The extracts and pure compounds from the plant were

however less active compared to ofloxacin, chlorophenicol and streptomycin which are known antibacterial compounds. Similarly for the antifungal tests, the extracts and pure compounds were less effective compared with known antifungal drugs such as amphotericin B, miconazole and fluconazole.

Acknowledgement(s)

The authors are thankful to Kenya Medical Research Institute (KEMRI), Kisumu, Kenya for the use of their laboratory to perform the biological activity tests. Mr. Mathenge of Botany Department, Nairobi University is highly thanked for identification of the plant. Dr. Serem of Maseno University clinic is acknowledged for the identification of the bacteria and fungi.

Authors Contribution(s)

All others contributed equally

References

1. Agnew ADQ, Agnew S. Kenya Upland Wild Flowers. East African Natural History, Nairobi, Kenya, 1994.
2. Kokwaro JO. Medicinal Plants of East Africa. East African Literature Bureau, Nairobi, Kenya, 1976.
3. Zdero C, Bohlmann F, Mungai GM. Seco-clerodanes and other diterpenes from *Conyza welwitschii*. *Phytochemistry* 1990; 29(7): 2247-2252.
4. Pandey CU, Ashok K, Singhal A K, Nabin C, Barua CN, Sharma RP, Jogendra N, Baruah JN, Watanabe K, Palaniappan KP, Herz W. Stereochemistry of strictic acid and related furano-diterpenes from *Conyza japonica* and *Grangea maderasptana*. *Phytochemistry* 1984;23: 391-397.
5. Bohlmann F, Wagner P. Three diterpenes from *Conyza podocephala*. *Phytochemistry* 1982; 21:1693-1695.
6. Chaudhry AB, Janbaz KH, Uzair M, Ejaz AS. biological studies of conyza and euphorbia species. *J. Res. (Science)* 2001; 12 (1): 85-88.
7. Mata R, Acevedo L, Bye R, Calzada F, Estrada S, Linares E, Rajas A, Rojas I. Smooth muscle relaxing flavonoids and terpenoids from *Conyza filaginoides*. *Planta Med.* 1997; 63 (1): 31-35.
8. Calzada F, Cedillo-Rivera R, Mata R. Antiprotozoal activity of the constituents of *Conyza filaginoides*. *J. Nat.Prod.* 2001; 64 (5): 671-673.
9. Xu I, Gou D, Liu J, Min D, Wang S, Zhang Z, Zheng K. Chemical constituents of *Conyza blinni*. *Zhongguo Hung Yahoo Zazhi* 1998; 23 (9): 552-557.
10. Picciaroni AD, Espinar LA, Ciccia G., Mongelli E, Ramano A, Silva G.L. Bioactive constituents of *Conyza albida*. *Planta Med.* 2000; 66(8): 720-723.
11. de las Heras B, Slowing K, Benedí J, Carretero E, Ortega T, Toledo C, Bermejo P, Iglesias I, Abad MJ, Gómez-Serranillos P, Liso PA, Villar A, Chiriboga X. Anti-inflammatory and antioxidant activity of plants used in traditional medicine in Ecuador. *J. Ethnopharmacology* 1998; 61: 161-166.
12. Opiyo SA, Ogur JA, Manguro LOA, Tietze LF, Schuster H. A new sterol diglycoside from *Conyza floribunda*. *South Afri. J. Chem* 2009; 62:9-13.
13. Anjaneyulu ASR, Narayana-Rao M. Elaeodendrol and elaeodendradiol: a new nor-triterpenes from *Elaeodendron glaucum*. *Phytochemistry* 1980; 19: 1163-1169.
14. Manguro LOA, Ugi I, Lemmen P. Flavonol glycosides of *Embelia schimperi*. *Bull. Chem. Soc. Ethiop.* 2004;18 (1): 51-57.
15. Akinpelu DA, Kolawole DO. Phytochemical and antimicrobial activity of leaf extract of *Piliostigma thioningii* (Schum). *Science Focus* 2004; 7: 64-70.
16. Widodo G.P, Sukandar EY, Adnyana IK. Coumarin from *Ageratum* leaves (*Ageratum conyzoides* L). *Intern. Pharmacol* 2008; 4(1): 56-59.
17. Diquid JR, Marmion BP, Swain RH. *Medical Microbiology*; Churchill Livingstone, London, UK, 1998.
18. Greenspan JS, Greenspan D. Oral complications in HIV infections. In: A. Sande, M. D. Paul and A. Volberding (Ed.), *the Management of AIDS*. Saunders, London, 1997.
19. Irobi ON, Moo-Young M, Anderson WA, Daramola SO. Antimicrobial activity of Annatto (*Bixa orellana*) extract. *Intern. Pharmacog.* 1996: 34:87-90.
20. Russeland AD, Furr JR. Antibacterial activity of a new chloroxyleneol preparation containing ethylenediamine tetraacetic acid. *J. Appl. Bacteriol.* 1977; 43: 253-260.
21. Igbinosa OO, Igbinosia EO, Aiyegoro O. Antimicrobial activity and phytochemical screening of stem bark extract from *Jatropha curcas* (Linn). *Afr. J. Pharm. pharmacol* 2009; 3: 58-62.

Illustrations

Illustration 1

Table 1. Antibacterial activity of *C. floribunda* CH₂Cl₂ and MeOH extracts

Zone of growth inhibition in mm (mean + SD)					
Bacteria	CH₂Cl₂	MeOH	oflaxacin	chlorophenicol	streptomycin
<i>S. pneumoniae</i>	14±0.2	16±0.3	25±0.1	27±0.1	22±1.0
<i>S. aureus</i>	12±0.6	16±0.4	28±0.5	28±0.4	20±0.3
<i>E. coli</i>	8±0.8	12±0.5	25±0.16	19±0.5	0±0

Illustration 2

Table 2. Antifungal activity of *C. floribunda* CH₂Cl₂ and MeOH extracts

Zone of growth inhibition in mm (mean + SD)					
Fungi	CH₂Cl₂	MeOH	miconazole	Amphotericin B	fluconazole
<i>C. albicans</i>	16±1.0	19±0.1	29±1.0	32±1.1	29±1.2
<i>T. mentagrophytes</i>	14±0.5	16±1.1	22±0.2	29±0.4	20±0
<i>M. gypseum</i>	10±0	14±0.3	24±0.6	26±0.1	21±1.0

Illustration 3

Table 3. Antibacterial activity of *C. floribunda* CH₂Cl₂ and MeOH extract fractions.

Zone of growth inhibition in mm (mean + SD)						
	CH ₂ Cl ₂ fractions				MeOH fractions	
Bacteria	Pool I	Pool II	Pool III	Pool IV	Pool V	Pool VI
<i>S. pneumoniae</i>	0±0	0±0	10±0.3	12±0.5	14±0.1	14±0.2
<i>S. aureus</i>	0±0	4±0.5	12±0.4	12±0	14±0.2	14±0.3
<i>E. coli</i>	0±0	0±0	4±0.6	6±03	10±0.3	10±1.2

Illustration 4

Table 4. Antifungal activities of *C. floribunda* CH₂Cl₂ and MeOH fractions

Zone of growth inhibition in mm (mean + SD)						
	CH ₂ Cl ₂ fractions				MeOH fractions	
Fungi	Pool I	Pool II	Pool III	Pool IV	Pool V	Pool VI
<i>C. albicans</i>	0±0	4±0.2	12±0.3	14±0.1	16±0.2	16±0.5
<i>T. mentagrophytes</i>	0±0	6±1.0	12±0.6	12±0.3	14±0.1	14±1.3
<i>M. gypseum</i>	0±0	0±0	0±0	0±0	14±1.0	12±1.2

Illustration 5

Table 5. Minimum inhibitory concentration (MIC, $\hat{\mu}$ g/ml) of pure compounds and standard antibiotics.

compound/ antibiotic	Bacteria			Fungi		
	S. pneumoniae	S. aureus	E. coil	C. albicans	T. mentagrophytes	M. gypseum
2	50	50	>100	25	50	100
3	50	50	100	25	50	50
7	100	100	>200	100	100	>200
10	100	100	>200	50	100	100
chorophenicol	6.25	3	1.5	ND	ND	ND
ofloxacin	6.25	6.25	3	ND	ND	ND
streptomycin	12.5	6.25	ND	ND	ND	ND
miconazole	ND	ND	ND	6.25	6.25	3
amphoterecin B	ND	ND	ND	6.25	3	6.25
fluconazole	ND	ND	ND	12.5	12.5	6.25

Disclaimer

This article has been downloaded from WebmedCentral. With our unique author driven post publication peer review, contents posted on this web portal do not undergo any prepublication peer or editorial review. It is completely the responsibility of the authors to ensure not only scientific and ethical standards of the manuscript but also its grammatical accuracy. Authors must ensure that they obtain all the necessary permissions before submitting any information that requires obtaining a consent or approval from a third party. Authors should also ensure not to submit any information which they do not have the copyright of or of which they have transferred the copyrights to a third party.

Contents on WebmedCentral are purely for biomedical researchers and scientists. They are not meant to cater to the needs of an individual patient. The web portal or any content(s) therein is neither designed to support, nor replace, the relationship that exists between a patient/site visitor and his/her physician. Your use of the WebmedCentral site and its contents is entirely at your own risk. We do not take any responsibility for any harm that you may suffer or inflict on a third person by following the contents of this website.